利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.024 秒)

    Topical oestroprogestational compositions with a systemic effect
    1.
    发明授权
    Topical oestroprogestational compositions with a systemic effect 失效
    具有全身作用的局部使用雌二醇组合物

    公开(公告)号：US07030104B2

    公开(公告)日：2006-04-18

    申请号：US10129040

    申请日：2001-09-14

    申请人： Georges Gray ,  Bertrand Villet ,  Jacques Paris ,  Jean-Louis Thomas

    发明人： Georges Gray ,  Bertrand Villet ,  Jacques Paris ,  Jean-Louis Thomas

    IPC分类号： A61K31/56 ,  A61K9/14 ,  A61K9/00

    CPC分类号： A61K9/0014 ,  A61K9/06 ,  A61K9/7015 ,  A61K31/57 ,  A61K31/565 ,  A61K2300/00

    摘要： The present invention relates to the field of therapeutic chemistry and more especially to the realization of new galenic forms intended to be applied on the skin.More particularly it relates to a topical hormonal composition with a systemic effect for the hormonal treatment of the perimenopause and of the menopause as well as for the treatment of the ovarian hormonal deficiencies in women with amenorrhea, characterized in that it comprises, as active ingredients, a progestogen derived from 19-nor progesterone and estradiol or one of its derivatives, a vehicle which allows the systemic passage of said active ingredients, chosen from the group constituted by a solubilizing agent, an absorption promoting agent, a film-forming agent, a gelling agent and their mixtures, in combination or in a mixture with suitable excipients for the realization of a gelled and/or film-forming pharmaceutical form.

    摘要翻译： 本发明涉及治疗化学领域，更具体地涉及旨在应用于皮肤的新的盖仑型形式的实现。 更具体地说，本发明涉及一种局部激素组合物，具有用于激素治疗围绝经期和绝经期以及用于治疗闭经妇女的卵巢激素缺乏的全身效应，其特征在于，其包含作为活性成分的， 衍生自19-没有孕酮和雌二醇或其衍生物之一的孕激素，其允许所述活性成分的全身通过，所述载体选自由增溶剂，吸收促进剂，成膜剂， 胶凝剂及其混合物，组合或与合适的赋形剂的混合物，以实现胶凝和/或成膜药物形式。

    NEW HORMONAL COMPOSITION AND ITS USE
    2.
    发明申请
    NEW HORMONAL COMPOSITION AND ITS USE 审中-公开
    新型HORMONAL组合物及其用途

    公开(公告)号：US20130172300A1

    公开(公告)日：2013-07-04

    申请号：US13448953

    申请日：2012-04-17

    申请人： Jacques Paris ,  Jean-Louis Thomas

    发明人： Jacques Paris ,  Jean-Louis Thomas

    IPC分类号： A61K31/57 ,  A61K31/567 ,  A61K31/565

    CPC分类号： A61K31/57 ,  A61K31/565 ,  A61K31/567 ,  A61K45/06 ,  A61K2300/00

    摘要： A method of preventing estrogen deficiencies and osteoporosis in menopausal women by continuously orally administering without interruption to menopausal women in need thereof an amount of 0.3 to 3 mg of 17β-estradiol or esters thereof and 0.3 to 1.25 mg of nomegestrol or esters thereof in an amount sufficient to prevent said problems.

    摘要翻译： 一种通过不间断地口服给予需要的绝经妇女不断口服绝经期女性的雌激素缺乏和骨质疏松症的方法，其量为0.3至3mg，17β-雌二醇或其酯，和0.3至1.25mg的炔雌醇或其酯， 足以防止所述问题。

    Topical hormonal composition with systemic action
    10.
    发明申请
    Topical hormonal composition with systemic action 审中-公开
    具有全身作用的局部荷尔蒙组成

    公开(公告)号：US20080227763A1

    公开(公告)日：2008-09-18

    申请号：US12077665

    申请日：2008-03-20

    申请人： Michel Lanquetin ,  Jacques Paris ,  Jean-Louis Thomas

    发明人： Michel Lanquetin ,  Jacques Paris ,  Jean-Louis Thomas

    IPC分类号： A61K31/57

    CPC分类号： A61K47/10 ,  A61K9/0014 ,  A61K9/7015 ,  A61K31/57 ,  A61K47/14 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

    摘要： The present invention relates to the area of chemotherapy and more especially to the development of new galenic forms for application to the skin.It relates more particularly to a topical hormonal composition with systemic action for the correction of progesterone deficiency in premenopausal women and for hormone replacement in menopausal women, characterized in that it contains, as the active principle, a progestogen derived from 19-nor progesterone, a vehicle permitting systemic passage of the said active principle chosen from the group comprising a solubilizing agent, an absorption promoter, a film-forming agent, a gelling agent or their mixtures, combined with or mixed with suitable excipients for production of a pharmaceutical form as a gel and/or a film.

    摘要翻译： 本发明涉及化学疗法的领域，更具体地涉及用于皮肤应用的新的盖仑制剂形式的开发。 更具体地涉及具有系统性作用的局部激素组合物，其用于矫正绝经前妇女中的孕酮缺乏和绝经妇女的激素替代，其特征在于，其包含作为活性成分的源自19-孕酮的孕激素， 允许所述活性成分的全身通过，所述活性成分选自包含增溶剂，吸收促进剂，成膜剂，胶凝剂或它们的混合物的组，与合适的赋形剂组合或与其混合，用于制备药物形式 凝胶和/或膜。